Regeneron和Roche先发制人,提供有前途的减重药品,并取得强有力的试验结果,有可能对顶级市场参与者构成挑战。 Regeneron and Roche advance promising weight-loss drugs with strong trial results, potentially challenging top market players.

Regeneron和Roche正在推进有前途的减重药物,有可能成为顶尖球员的对手。 Regeneron and Roche are advancing promising weight-loss drugs with potential to rival top players. Regeneron的 trevogrumab在第二阶段可能会减少体重下降期间的肌肉损失,其GLP-1候选人的olatorepatide定于2026年进行第三阶段试验。 Regeneron’s trevogrumab, in phase 2, may reduce muscle loss during weight loss, and its GLP-1 candidate olatorepatide is set for phase 3 trials in 2026. Roche的CT-388显示,第2阶段的平均体重下降率为22.5%,第3阶段的数据待定。 Roche’s CT-388 showed 22.5% average weight loss in phase 2, with phase 3 data pending. 这两家公司都受益于多样化的投资组合和强大的输油管,减少了对任何单一药物的成功的依赖。 Both companies benefit from diversified portfolios and strong pipelines, reducing reliance on any single drug’s success.